Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Eli Lilly and Company (LLY, Financials) said tirzepatide drastically reduced the risk of type 2 diabetes in pre-diabetics and ...

Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Eli Lilly (LLY) and Company announced detailed results from the Phase 3 SURMOUNT-1 three-year study, the longest completed study to date of ...

Tirzepatide is a dual acting ... Just any any advice to us when we start to look at longevity and the longevity economy? How ...

Officials say it's a good sign for the industry that tirzepatide, sold under the brand ... drug off the shortage list after pushback, but Eli Lilly confirmed to FOX Business on Tuesday that ...

Conditions are getting a bit more challenging for the drugmaker.

Susan McGowan, a 58-year-old nurse from Scotland, tragically passed away after taking two doses of tirzepatide, a weight-loss ...

Eli Lilly and Co. plans to set up a $31 million digital health ... that does clinical trials on drugs for diabetes and ...